Skip to main content

Table 6 Cox analysis of metastasis-free survival (MFS) in the molecular subtypes (ER+/HER; ER-/HER2-; HER2+) according to Desmedt and co-workers [[31]]

From: Expression of aurora kinase A is associated with metastasis-free survival in node-negative breast cancer patients

 

p

HR

95% CI

B. Multivariate analysis

ER+/HER2- (n=332)

Age (<50 vs. ≥50 years)

0.920

1.025

0.634-1.656

pT stage (≤2cm vs. >2cm)

0.004

2.143

1.271-3.613

Histological grade (Grade 1 and 2 vs. grade 3)

0.456

1.255

0.691-2.283

AURKA (continuous variable)

0.001

1.734

1.242-2.419

 

p

HR

95 % CI

ER-/HER2- (n=80)

Age (<50 vs. ≥50 years)

0.644

0.825

0.365-1.865

pT stage (≤2cm vs. >2cm)

0.466

1.459

0.528-4.028

Histological grade (Grade 1 and 2 vs. grade 3)

0.590

0.768

0.294-2.005

AURKA (continuous variable)

0.858

0.943

0.497-1.791

 

p

HR

95 % CI

HER2+ (n=53)

Age (<50 vs. ≥50 years)

0.018

5.072

1.327-19.383

pT stage (≤2cm vs. >2cm)

0.485

1.510

0.475-4.802

Histological grade (Grade 1 and 2 vs. grade 3)

0.001

15.527

3.223-74.793

AURKA (continuous variable)

0.001

0.146

0.045-0.466

  1. AURKA is associated with MFS in the estrogen receptor positive but not in the estrogen receptor negative subtypes. B. Multivariate Cox regression.